Analyst Price Targets — PRAX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 21, 2026 10:23 am | — | Goldman Sachs | $575.00 | $364.58 | TheFly | Praxis Precision price target raised to $575 from $470 at Goldman Sachs |
| August 17, 2026 10:15 am | Tiago Fauth | Raymond James | $945.00 | $366.81 | StreetInsider | Praxis Precision Medicines Inc. (PRAX) PT Raised to $945 at Raymond James |
| August 7, 2026 12:26 pm | Leonid Timashev | RBC Capital | $462.00 | $363.81 | TheFly | Praxis Precision price target raised to $462 from $449 at RBC Capital |
| August 7, 2026 11:58 am | — | Robert W. Baird | $514.00 | $362.81 | TheFly | Praxis Precision price target raised to $514 from $400 at Baird |
| August 7, 2026 10:59 am | Benjamin Burnett | Wells Fargo | $362.00 | $370.16 | TheFly | Praxis Precision price target raised to $362 from $323 at Wells Fargo |
| July 13, 2026 9:24 am | — | Goldman Sachs | $447.00 | $324.99 | TheFly | Praxis Precision initiated with a Buy at Goldman Sachs |
| June 29, 2026 12:08 pm | Ami Fadia | Needham | $575.00 | $329.52 | TheFly | Praxis Precision price target raised to $575 from $510 at Needham |
| June 17, 2026 8:30 pm | Leonid Timashev | RBC Capital | $449.00 | $270.01 | TheFly | Praxis Precision initiated with an Outperform at RBC Capital |
| June 2, 2026 12:05 pm | — | Truist Financial | $616.00 | $306.06 | TheFly | Praxis Precision price target lowered to $616 from $715 at Truist |
| June 2, 2026 11:46 am | — | Wedbush | $162.00 | $335.16 | TheFly | Praxis Precision price target lowered to $162 from $166 at Wedbush |
Latest News for PRAX
Shares of Praxis Precision Medicines, Inc. (NASDAQ: PRAX - Get Free Report) have been assigned a consensus rating of "Buy" from the twenty-two analysts that are currently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, sixteen have given a buy rating and four have given a
Praxis Precision Medicines, Inc. (NASDAQ: PRAX - Get Free Report) shares reached a new 52-week high during mid-day trading on Tuesday. The company traded as high as $391.64 and last traded at $376.38, with a volume of 581487 shares traded. The stock had previously closed at $366.81. Analyst Upgrades and Downgrades Several analysts recently weighed
Handelsbanken Fonder AB acquired a new stake in Praxis Precision Medicines, Inc. (NASDAQ: PRAX) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 9,840 shares of the company's stock, valued at approximately $3,294,000. Several other hedge funds have also recently
Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.
Prax is analyzed using a sum-of-parts valuation approach, focusing on its lead asset, Ulixa. Recent updates from the Goldman Sachs presentation highlight key developments ahead of Ulixa's commercial launch. I assess PRAX's strategic positioning and upcoming catalysts tied to Ulixa's market entry.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PRAX.
U.S. House Trading
No House trades found for PRAX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.